Aktis Oncology
AKTS
NASDAQ
IPO2026
about AKTS
Aktis Oncology is a biopharmaceutical company focused on developing innovative therapies in targeted oncology, immuno-oncology, and precision medicine to enhance treatment options for cancer patients.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $19.97 | $20.79 | $19.48 | $1.1B | 169.92K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.04 | n/a | 345.91 | -59.11% | -71.12% | 0% |